Aratana Therapeutics Inc. reached a significant milestone Wednesday when its first drug, Nocita, hit the market. But Dr. Steven St. Peter, CEO of the Leawood-based pet biotech, said the company is on track to reach the ambitious goals set when it was founded in 2010.
“We never said it was easy — we said it was possible,” St. Peter said. “This is exactly the time frame we’ve been talking about for years.”
Aratana has been able to streamline the Food and Drug Administration approval process for animal and veterinary products to four to five years, St. Peter said. Other companies spend seven to 10 years navigating the regulatory framework.
To date, Aratana has scored three FDA approvals, all granted in 2016, on top of two licensed animal treatments from the U.S. Department of Agriculture.
Read more: Kansas City Business Journal